Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of JNJ-64041575 Formulations
NCT03010059Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lumicitabine in respiratory syncytial virus infection (RSV) (12 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration of ALS-008112, Area Under Plasma Concentration Curve from time zero to the last quantifiable concentration of ALS-008112 and 1 more. Started Feb 2017; status: completed.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03010059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03010059.